iBio, Inc. (IBIO) fair value: what the stock is really worth
As of Nov 18, 2026: fair value (intrinsic value) of iBio, Inc. stock $0.53, price $0.85, that is 37.8% below the price, quality 22 out of 100. Rating: strongly overvalued. The value is an estimate: none of our valuation models currently carries, it draws on revenue and assets compared with similar companies. Updated daily.
- Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free
iBio, Inc.
IBIO · USFar too expensive (fair value 38% below the price), weak company and falling price: meets none of the 3 rules.
What runs behind every stock
69 individual criteria per stock, every one traceable See the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year. As of Nov 14, 2026.
How to read this chart
60‑month range $0.5700 – $640.00 · fair‑value band $0.3957 – $0.6595 · the $0.8481 price screens above the $0.5276 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 14, 2026.
Every Wednesday you see whether iBio is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Company profile
iBio, Inc., a preclinical stage biotechnology company, engages in the development of artificial intelligence (AI) antibodies solutions for cardiometabolic and obesity space.
Show moreShow less
The company's technology platforms include EngageTx that provides improved CD3 T-cell engager antibody panel; ShieldTx, an antibody masking technology that enables the creation of conditionally activated antibodies; StableHu, an AI antibody-optimizing technology; and AI epitope steering technology that guides antibodies against the desired regions of the target protein.
Its product pipelines for cardiometabolic disease area include IBIO-101, an anti-CD25 Mab that binds and depletes immunosuppressive regulatory treg cells to inhibit the growth of solid tumors; CCR8, an antibody that enhance the body's immune response against cancer cells; and MUC16 antibodies.
In addition, the company is developing EGFRvIII, an antibody therapeutics that targets EGFRvIII protein with the aim to address these cancer types without affecting healthy cells; and TROP-2 x CD3 bispecific antibody that is developed with EngageTx platform to harness T cells to kill TROP-2"expressing tumors while minimizing the cytokine release that often limits the tolerability of T-cell engagers.
It has a collaboration agreement with AstralBio to discover and develop novel antibodies for obesity and other cardiometabolic diseases.
The company was formerly known as iBioPharma, Inc. and changed its name to iBio, Inc. in August 2009. iBio, Inc. was incorporated in 2008 and is headquartered in San Diego, California.
Stock analysis
iBio, Inc. (IBIO) currently trades at $0.8481, while our estimate is $0.5276, 38% below the price, so the stock looks overvalued today.
Show more
Valuation
None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.
Scenario range: $0.3957 (bear) to $0.6595 (bull), the price of $0.8481 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 22/100 (below-average quality), in the Healthcare sector.
Weak Growth: Revenue is shrinking: the last year, the last three and the last five years are all negative.
iBio, Inc. reported revenue of $100K in FY2026 versus $1.9M in FY2022, a compound −52.0%/yr. Reported net income was −$33.0M in FY2026.
Key figures
Market cap $88.3M Micro · P/S ratio 50.0 · EPS (TTM) $−0.2700 · Return on equity −51.8% · Return on assets (EBIT) −54.9% (5-year average) · Operating margin −3,026% · Revenue growth (YoY) +975% · Free cash flow −$23.8M.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 5 out of 100 (medium confidence).
What moves the price
The share trades about 72% below its 52-week high and 20% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −7% fair-value upside, at −38%, IBIO screens richer than that median.
Fair Value
Quality Score breakdown
It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.
Insider trades
In the last 6 months, no officer or director bought or sold shares on the open market.
- BuyMarc BanjakChief Legal Officer13,934 shares at $1.65$23,024Mar 26, 2026
- BuyMartin BrennerOfficer, Director12,336 shares at $2.02$24,919Mar 19, 2026
- BuyFelipe DuranChief Financial Officer24,835 shares at $2.02$50,167Mar 19, 2026
Sales are often planned (taxes, diversification, 10b5-1 plans). Purchases with their own money are seen as the stronger sign. For information only: not part of the quality score or Fair Value.
Source: SEC Form 4, as of Nov 18, 2026. All filings at the SEC ↗
Revenue & earnings trend
Compare iBio, Inc. with another stock
Price, fair value, quality and upside side by side.
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 851 stocks
Valuation Multiplesvs Biotechnology median · lower = cheaper
Strength profile in five axes (Snowflake)
VALUE 0: the price sits above our fair-value range.
Context: sector, industry, market
- Is the Health Care sector expensive or cheap?
- P/E, EV/EBITDA and margins by industry (reference tables)
- Revenue growth by industry
- PEG ratio by industry
- Piotroski F-Score screener with fair value
- Undervalued stocks: US Stocks
- Valuation of the USA market
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
Similar stocks
10 more Biotechnology stocks, each showing price versus our Fair Value estimate.
| Stock | Price | Fair Value | vs Fair Value | Compare |
|---|---|---|---|---|
| Regeneron Pharmaceuticals, Inc REGN | $945.53 | $1,275 | +35% | vs IBIO |
| Vertex Pharmaceuticals Incorporated VRTX | $536.45 | $587.62 | +10% | vs IBIO |
| Samsung Biologics Co 207940 | 1,375,000 KRW | 1,502,600 KRW | +9% | vs IBIO |
| argenx SE ARGX | $941.25 | $908.40 | −3% | vs IBIO |
| CSL Limited CSL | A$199.85 | A$186.49 | −7% | vs IBIO |
| Moderna, Inc MRNA | $196.79 | $135.64 | −31% | vs IBIO |
| BeOne Medicines AG 6160 | HK$242.60 | HK$152.92 | −37% | vs IBIO |
| Revolution Medicines, Inc RVMD | $159.82 | $83.12 | −48% | vs IBIO |
| Celltrion, Inc 068270 | 215,000 KRW | 74,945 KRW | −65% | vs IBIO |
| Royalty Pharma plc RPRX | $68.67 | $19.01 | −72% | vs IBIO |
Explore undervalued stocks
More undervalued Healthcare stocks →
Try a ready-made strategy
Pick a strategy and jump into the live analysis with that exact screen applied.
Discover tools
Frequently asked questions
Is iBio, Inc. (IBIO) overvalued or undervalued?
What is the fair value of IBIO?
What is the quality score of IBIO?
What is the price target for iBio, Inc. (IBIO)?
What is the iBio, Inc. stock forecast for 2026?
What is the intrinsic value of iBio, Inc. (IBIO)?
Is iBio, Inc. stock overvalued or undervalued in 2026?
Is fair value the same as the market price of IBIO?
How much is iBio, Inc. worth?
What do the bullish and bearish scenarios say about IBIO?
How solid is the balance sheet of iBio, Inc. (IBIO)?
How far is IBIO from its 52-week high?
Which stocks are comparable to iBio, Inc.?
Is iBio, Inc. stock attractive at the current price?
Is it still worth investing in stocks now?
What is the share price of iBio, Inc. (IBIO)?
What should I pay attention to with iBio, Inc. right now?
Key figures of iBio, Inc.
How large is the market capitalisation of iBio, Inc. (IBIO)?
What is the P/S ratio of iBio, Inc. (IBIO)?
What are the earnings per share of iBio, Inc. (IBIO)?
What is the return on equity of iBio, Inc. (IBIO)?
What is the EBIT return on assets of iBio, Inc. (IBIO)?
What is the operating margin of iBio, Inc. (IBIO)?
How fast is revenue growing at iBio, Inc. (IBIO)?
How much free cash flow does iBio, Inc. (IBIO) generate?
How much net cash does iBio, Inc. (IBIO) hold?
Watch iBio, Inc. in the live analysis
One click puts iBio, Inc. on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.
Watch for free →Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.